Fremanezumab Compassionate Use Program for Pediatric Patients With Migraine

Study Title
Fremanezumab (TEV-48125) Compassionate Use Program for Pediatric Patients (6 to 17 Years) With Chronic or Episodic Migraine
Teva Identifier
TV48125-CNS-80005
ClinicalTrials.gov Identifier
NCT03539393
Study Status
Available
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
6 Years to 17 years
Trial Duration
N/A
Phase
N/A

Study Type

Expanded Access: Treatment IND/Protocol